Precigen is a clinical-stage biopharmaceutical company improving gene and cell therapies. Co. is utilizing proprietary technology platforms to develop product candidates designed to diseases in its therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Co. is developing its clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. In addition, Co. has completed a Phase 1 study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on its UltraVector platform. We show 17 historical shares outstanding datapoints in our PGEN shares outstanding history coverage, used to compute PGEN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PGEN market cap history over the course of time is important for investors
interested in comparing PGEN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PGEN versus a peer is one thing; comparing
PGEN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PGEN can fluctuate over the course of history.
With this page we aim to empower investors researching PGEN by allowing them to research the PGEN market cap history. |
Free PGEN Email Alerts:
Video: The Importance of Market Cap
